These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8081411)

  • 21. Genetic polymorphism of cytochromes P450: interethnic differences and relationship to incidence of lung cancer.
    Ingelman-Sundberg M; Johansson I; Persson I; Yue QY; Dahl ML; Bertilsson L; Sjöqvist F
    Pharmacogenetics; 1992 Dec; 2(6):264-71. PubMed ID: 1306127
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polymorphism of human CYP2D genes involved in drug metabolism: possible relationship to individual cancer risk.
    Nebert DW
    Cancer Cells; 1991 Mar; 3(3):93-6. PubMed ID: 2054261
    [No Abstract]   [Full Text] [Related]  

  • 23. Lack association between schizophrenia and the CYP2D6 gene polymorphisms.
    Pirmohamed M; Wild MJ; Kitteringham NR; O'Brien K; Buchan IE; Back DJ; Park BK
    Am J Med Genet; 1996 Apr; 67(2):236-7. PubMed ID: 8723057
    [No Abstract]   [Full Text] [Related]  

  • 24. Debrisoquine 4-hydroxylation (CYP2D6) polymorphism in Jordanians.
    Hadidi HF; Cholerton S; Monkman SC; Armstrong M; Irshaid YM; Rawashdeh NM; Daly AK; Idle JR
    Pharmacogenetics; 1994 Jun; 4(3):159-61. PubMed ID: 7920696
    [No Abstract]   [Full Text] [Related]  

  • 25. CYP2D6 genes and risk of liver cancer.
    Agúndez JA; Ledesma MC; Benítez J; Ladero JM; Rodríguez-Lescure A; Díaz-Rubio E; Díaz-Rubio M
    Lancet; 1995 Apr; 345(8953):830-1. PubMed ID: 7898230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interpretation of a simple PCR analysis of the CYP2D6(A) and CYP2D6(B) null alleles associated with the debrisoquine/sparteine genetic polymorphism.
    Douglas AM; Atchison BA; Somogyi AA; Drummer OH
    Pharmacogenetics; 1994 Jun; 4(3):154-8. PubMed ID: 7920695
    [No Abstract]   [Full Text] [Related]  

  • 27. CYP2D6-debrisoquine hydroxylase gene polymorphism in multiple system atrophy.
    Planté-Bordeneuve V; Bandmann O; Wenning G; Quinn NP; Daniel SE; Harding AE
    Mov Disord; 1995 May; 10(3):277-8. PubMed ID: 7651442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of genetic differences in debrisoquine hydroxylase activity.
    Wolf CR; Spurr NK
    Hepatology; 1992 Feb; 15(2):360. PubMed ID: 1735543
    [No Abstract]   [Full Text] [Related]  

  • 29. Genetic polymorphism of debrisoquine oxidation: restriction fragment analysis and allele-specific amplification of mutant alleles of CYP2D6.
    Heim MH; Meyer UA
    Methods Enzymol; 1991; 206():173-83. PubMed ID: 1686063
    [No Abstract]   [Full Text] [Related]  

  • 30. Debrisoquine hydroxylase gene polymorphism frequencies in patients with amyotrophic lateral sclerosis.
    Siddons MA; Pickering-Brown SM; Mann DM; Owen F; Cooper PN
    Neurosci Lett; 1996 Apr; 208(1):65-8. PubMed ID: 8731176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of debrisoquine phenotype.
    Wolf CR; Moss JE; Miles JS; Gough AC; Spurr NK
    Lancet; 1991 Mar; 337(8741):623. PubMed ID: 1671985
    [No Abstract]   [Full Text] [Related]  

  • 32. Debrisoquine 4-hydroxylase (CYP2D) locus and possible susceptibility to schizophrenia.
    Vallada H; Collier D; Dawson E; Owen M; Nanko S; Murray R; Gill M
    Lancet; 1992 Jul; 340(8812):181-2. PubMed ID: 1352597
    [No Abstract]   [Full Text] [Related]  

  • 33. A novel cytochrome P-450IID6 (CYPIID6) mutant gene associated with multiple system atrophy.
    Iwahashi K; Miyatake R; Tsuneoka Y; Matsuo Y; Ichikawa Y; Hosokawa K; Sato K; Hayabara T
    J Neurol Neurosurg Psychiatry; 1995 Feb; 58(2):263-4. PubMed ID: 7876880
    [No Abstract]   [Full Text] [Related]  

  • 34. CYP2A6 polymorphism, nicotine, and environmental nitrosamines.
    Idle JR
    Lancet; 1999 Jun; 353(9169):2073. PubMed ID: 10376647
    [No Abstract]   [Full Text] [Related]  

  • 35. [Genetic polymorphism of drug metabolizing enzymes].
    Yokoi T; Kamataki T
    Seikagaku; 1997 Oct; 69(10):1196-9. PubMed ID: 9431010
    [No Abstract]   [Full Text] [Related]  

  • 36. Susceptibility to astrocytoma and meningioma: influence of allelism at glutathione S-transferase (GSTT1 and GSTM1) and cytochrome P-450 (CYP2D6) loci.
    Elexpuru-Camiruaga J; Buxton N; Kandula V; Dias PS; Campbell D; McIntosh J; Broome J; Jones P; Inskip A; Alldersea J
    Cancer Res; 1995 Oct; 55(19):4237-9. PubMed ID: 7671227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility.
    Wolf CR; Smith CA; Gough AC; Moss JE; Vallis KA; Howard G; Carey FJ; Mills K; McNee W; Carmichael J
    Carcinogenesis; 1992 Jun; 13(6):1035-8. PubMed ID: 1600608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of CYP2D6 expression in human lung: implications for the association between CYP2D6 activity and susceptibility to lung cancer.
    Kivistö KT; Griese EU; Stüven T; Fritz P; Friedel G; Kroemer HK; Zanger UM
    Pharmacogenetics; 1997 Aug; 7(4):295-302. PubMed ID: 9295057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of debrisoquine hydroxylation phenotypes.
    Wolf CR; Moss JE; Miles JS; Gough AC; Spurr NK
    Lancet; 1990 Dec; 336(8728):1452-3. PubMed ID: 1978915
    [No Abstract]   [Full Text] [Related]  

  • 40. Debrisoquine hydroxylase gene polymorphism in familial Parkinson's disease.
    Planté-Bordeneuve V; Davis MB; Maraganore DM; Marsden CD; Harding AE
    J Neurol Neurosurg Psychiatry; 1994 Aug; 57(8):911-3. PubMed ID: 8057112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.